Skip to content
星期五, 3 二月, 2023
Latest:
  • 智慧財產
  • 媒體新聞
  • 獲獎實績
  • 學術發表
長弘生物科技股份有限公司

長弘生物科技股份有限公司

研發抗癌藥物的明日之星

  • 關於長弘
  • 創辦人的話
  • 產品研發
  • 智慧財產
  • 最新消息
  • 聯絡我們
  • EN

Author: jacky

產品研發 

B. HK-001對抗漸凍症

2019-09-032020-12-29 jacky

HK-001由調控自體吞噬作用來延緩肌萎

Read more
產品研發 

C. EF-009對抗胰臟癌

2019-09-032019-12-12 jacky

小分子”DNA甲基轉移酶”EF-009

Read more
產品研發 

D. EF-005對抗阿茲海默症

2019-09-032019-12-12 jacky

阿茲海默症iPS 幹細胞篩選出治療之新穎

Read more
產品研發 

產品研發

2019-09-032022-06-06 jacky

A. Cerebraca Wafer 對

Read more
未分類 

創辦人的話

2019-09-032020-12-29 jacky

長弘生物科技股份有限公司 創辦人 陳和錦

Read more
關於長弘 

關於長弘

2019-08-222022-06-08 jacky

  長弘生物科技股份有限公司在總裁陳和錦

Read more
  • Next →

EN NEWS

  • Local delivery therapy of Cerebraca® Wafer being highlighted in the natural review
    2022-06-27
  • Case report – Cerebraca® Wafer implantation combined with CIK therapy for the treatment of recurrent Glioblastoma revealed superior clinical outcome (overall survival extended for more than 24 months).
    2022-06-27
  • Case report – Cerebraca® Wafer implantation for the treatment of un-resectable cervical spine Glioblastoma resulted in the tumor regression.
    2022-06-27
  • Outstanding clinical outcomes were published in various journals. We have listed as follows:
    2022-06-27
Copyright © 2023 長弘生物科技股份有限公司. All rights reserved.
Theme: ColorMag by ThemeGrill. Powered by WordPress.